<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426254</url>
  </required_header>
  <id_info>
    <org_study_id>TST-9-H</org_study_id>
    <nct_id>NCT03426254</nct_id>
  </id_info>
  <brief_title>Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors</brief_title>
  <official_title>Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Trials &amp; Treatment</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioGene Pharmaceutical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center Trials &amp; Treatment</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of two forms of Talazoparib therapy (injections&#xD;
      subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics&#xD;
      dose&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intent of this study was to assess the safety and efficacy of two forms of Talazoparib&#xD;
      therapy for the treatment of advanced solid tumors . After an enrollment period, patients&#xD;
      will randomized to receive oral Talazoparib (1 mg, one times a day ) or subcutaneously&#xD;
      Talazoparib (1 mg by subcutaneous injection with NovoPen / Autopen) one times a day in the&#xD;
      appropriate volume&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The intent of this study was to assess the safety and efficacy of two forms of Talazoparib therapy for the treatment of advanced solid tumors . After an enrollment period, patients will randomized to receive oral Talazoparib (1 mg, one times a day ) or subcutaneously Talazoparib (1 mg subcutaneous injection by pen-syringe / mechanical dispenser) .</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence and evaluation of adverse events in the use of Subcutaneously Talazoparib ( 1 mg / dose )</measure>
    <time_frame>Anticipated in about 12 month following first patient enrolled</time_frame>
    <description>Frequency of occurrence and evaluation of adverse events in the use of Subcutaneously Talazoparib , assessed by percentage of patients with any Adverse Event (AE), leading to Study Drug Discontinuation, Serious Adverse Event (SAE), related to study drug, SAE related to study drug.&#xD;
Incidence of toxicity, graded according to the National Cancer Institute (NCI) CTCAE version 4.03 Incidence of toxicity, graded according to the National Cancer Institute (NCI) CTCAE version 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit of Injections Subcutaneously Talazoparib</measure>
    <time_frame>Every 9 weeks for 12 months</time_frame>
    <description>Clinical benefit (CB) defined as any of the following, complete response, partial response, or stable disease for &gt; 24 weeks by RECIST 1.1. Assessments performed using computed tomography (CT) or magnetic resonance imaging (MRI) or ultrasound examination (Use) scan every 9 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Advanced or Recurrent Solid Tumors</condition>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Injections Subcutaneously Talazoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Auto-Injector delivers a single dose of 1 mg Talazoparib injection (subcutaneous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral capsules Talazoparib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 1 mg of Talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injections Subcutaneously Talazoparib</intervention_name>
    <description>Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28</description>
    <arm_group_label>Injections Subcutaneously Talazoparib</arm_group_label>
    <other_name>MDV3800</other_name>
    <other_name>BMN673</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral capsules Talazoparib</intervention_name>
    <description>Patients receive 1 mg of Talazoparib PO QD on days 1-28.</description>
    <arm_group_label>Oral capsules Talazoparib</arm_group_label>
    <other_name>MDV3800</other_name>
    <other_name>BMN673</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent form (by the patient or a legally acceptable&#xD;
             representative as per the local regulations) obtained prior to initiation of any&#xD;
             study-specific procedure and treatment.&#xD;
&#xD;
          -  Female of at least 21 years of age.&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor with no available&#xD;
             standard approved treatment options in the opinion of the Investigator&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ≤ 2.&#xD;
&#xD;
          -  Renal function at screening and enrollment as defined by the&#xD;
&#xD;
          -  Patient has had no clinically significant change in renal status within 3 months prior&#xD;
             to screening, according to Investigator's review of clinical patient records.&#xD;
&#xD;
          -  Patient is not currently on hemodialysis and/or peritoneal dialysis for management of&#xD;
             chronic kidney disease or acute failure/conditions.&#xD;
&#xD;
          -  Patient has no unstable renal function, defined as a change in estimated glomerular&#xD;
             filtration rate (eGFR) (calculated with the MDRD equation) of &gt; 25% for patients with&#xD;
             mild and moderate renal impaired or as a change in eGFR &gt; 30% for patients with severe&#xD;
             renal impaired, from screening to enrollment.&#xD;
&#xD;
          -  Received at least 1 and no more than 3 platinum-based chemotherapy regimens (prior&#xD;
             bevacizumab is allowed) and the last dose is ≥ 28 days before randomization&#xD;
&#xD;
          -  No prior PARP inhibitor treatment&#xD;
&#xD;
          -  Adequate other organ function at screening and enrollment.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening, and must agree to use a highly effective birth control method from the time&#xD;
             of the first dose of study drug through 60 days after the last dose of study drug.&#xD;
&#xD;
          -  Female patients must not be breastfeeding at screening nor during the study&#xD;
             participation until 60 days after the last dose of study drug.&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests, and other trial procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminology Criteria for Adverse Events [CTCAE] grade ≤ 1) from the acute toxicities&#xD;
             of previous therapy, except treatment-related alopecia or laboratory abnormalities&#xD;
             otherwise meeting eligibility requirements.&#xD;
&#xD;
          -  Use of any investigational agent within 14 days before randomization.&#xD;
&#xD;
          -  Had &gt; 2 paracentesis procedures within 28 days before randomization.&#xD;
&#xD;
          -  Major surgery within 14 days before randomization.&#xD;
&#xD;
          -  Requirement for intravenous alimentation (at the time of randomization).&#xD;
&#xD;
          -  Seropositive for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Any serious or unstable medical condition that interferes with ability to tolerate&#xD;
             treatment or assessments associated with the protocol.&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any of the talazoparib capsule components.&#xD;
&#xD;
          -  Any condition or reason that interferes with ability to participate in the study,&#xD;
             tolerate treatment or assessments associated with the protocol, causes undue risk, or&#xD;
             complicates the interpretation of safety data, in the opinion of the Investigator or&#xD;
             Medical Monitor.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Central Contact</last_name>
    <email>info@trials.clinic</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oleg Martynenko</last_name>
    <phone>+380997805042</phone>
    <email>info@trials.clinic</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University -Mother Theresa- Hospital, Oncology Dep.</name>
      <address>
        <city>Tirana</city>
        <zip>1</zip>
        <country>Albania</country>
      </address>
    </facility>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioGene Pharmaceutical</name>
      <address>
        <city>Zürich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneously Talazoparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

